Cinda Bio published the results of the clinical study of the same line of treatment for advanced liver cancer phase III

ORIENT-32 is the world's first PD-1 inhibitor combined treatment for advanced first-line treatment of hepatitis B virus (HBV)-related liver cancer in the major population of randomized, open, multi-center III studies.
study involved 571 subjects in the group, and based on in-period analysis conducted by the Independent Data Monitoring Board (IDMC), Dabershu® (Syndili monoantigenic injection) combined with ® (Beval pearl monoantigenic injection) compared to sorafini monodrative therapy, significantly extending total survival (OS) and non-progressive survival (PFS) to achieve pre-established optimal effectiveness standards.
, the risk of death decreased by 43.1 per cent® (HR 0.569) compared to the Sorafini group, ® 95% CI: 0.431-0.751, P®®.lt;0.0001);
risk of disease progressity assessed by the Independent Imaging Commission (IRRC) based on RECIST 1.1 decreased by 43.5% (HR 0.565), 95%CI: 0.455-0.701, P.lt;0.0001), Dabershu® Union PfS was 4.6 months in group ®, and the middle PFS in the Sorafini group was 2.8 months.
subgroup analysis showed that all subgroup combined treatment groups benefited.
treatment options have acceptable safety and no new safety signals.
D'® therapy promises ® new options for first-line treatment for patients with non-excision or metastatic liver cancer.
note: There are deletions in the original text